Tumor angiogenesis in predicting the survival of patients with stage I lung cancer  by Medetoglu, Baris et al.
G
T
S
General Thoracic Surgery Medetoglu et alTumor angiogenesis in predicting the survival of patients with stage I
lung cancerBaris Medetoglu, MD,a Mehmet Zeki Gunluoglu, MD,a Adalet Demir, MD,a Huseyin Melek, MD,a
Nur Buyukpinarbasili, MD,b Neslihan Fener, MD,b and Seyyit Ibrahim Dincer, MDaFrom th
Hosp
Disclosu
Receive
public
Address
A-3 B
0022-52
Copyrig
doi:10.1
996Objective: The effects of angiogenesis on survival were assessed by measuring the tumor microvessel density
and vascular endothelial growth factor expression in patients with resected stage I non–small cell lung carcinoma.
Methods: The study population included 141 patients who underwent complete resection for stage pT1 and T2
N0 M0 tumors between 1999 and 2007. Lobectomy and pneumonectomy were performed in 131 and 10 patients,
respectively. Tumor specimens were analyzed immunohistochemically for staining with anti-CD105 antibody to
determine tumor microvessel density and anti–vascular endothelial growth factor antibody to determine the
vascular endothelial growth factor expression level. Univariate and multivariate analyses were performed for
factors influencing patients’ survival.
Results: The overall 5-year survival was calculated as 68%, with rates of 76.9% for patients with T1 disease and
66.2% for patients with T2 disease (P ¼ .4). The vascular endothelial growth factor expression rate was 94.3%
for patients with stage I non–small cell lung carcinoma. Vascular endothelial growth factor expression did not
influence survival (P ¼ .9). The median microvessel density of the tumors measured based on the level of
CD105 expression was 19.8. The effect of microvessel density on survival was significant (P ¼ .02). The
5-year survivals of patients with tumors with 20 or more microvessels and less than 20 microvessels were
76.8% and 56.1%, respectively; this difference was highly significant (P ¼ .004). The microvessel density
was determined as an independent factor influencing survival on multivariate analysis (P ¼ .03).
Conclusions: The level of vascular endothelial growth factor expression in tumors was not a successful predictor
of survival in patients with resected stage I non–small cell lung carcinoma. A high microvessel density based on
CD105 is a strong predictor of prognosis in these patients. (J Thorac Cardiovasc Surg 2010;140:996-1000)Most patients with non–small cell lung cancer (NSCLC)
who survive for a long time have tumors at TNM stage I
or II at the time of initial diagnosis. However, despite poten-
tially curative treatment, the 5-year survival is not yet
satisfactory, even in these patients.1,2
Many factors considered to affect prognosis in patients
with NSCLC have been and are still being investigated. Im-
provements in our understanding of the genetic and molec-
ular basis of lung cancer in recent years have led to the
discovery and assessment of new factors that might be of
prognostic value. The level of neoangiogenesis in the tumor
tissue is one of the factors assessed previously.3 The density
of vascular structures in the tumor tissue can be determined
by means of immunohistochemical staining of the tissue for
the endothelial cell marker CD105 (endoglin).4 One of the
factors known to affect the level of neoangiogenesis is
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The Journal of Thoracic and Cardiovascular Surgexpression of which in tumor tissue can also be determined
by using immunohistochemical staining. Several studies
have examined the effects of tumor VEGF and CD105
expression in patients with NSCLC but yielded inconsistent
results. Moreover, TNM stages of the patient populations
were heterogeneous or the tumors were limited to only 1 his-
topathological type in most of these studies.
The present study was performed to assess the effects of
the expression levels of the major neoangiogenesis markers
CD105 and VEGF in tumor tissue, as measured with immu-
nohistochemical methods, on the survival of patients with
completely resected stage I NSCLC.MATERIALS AND METHODS
Our clinical database was searched to find patients with stage I (T1 or T2
and N0 M0) NSCLC surgically treated between January 1999 and January
2007. During this period, 557 consecutive lung resections because of
NSCLC were performed. One hundred sixty-nine patients with pathologi-
cally diagnosed stage I NSCLC were found (30% of all of the patients).
Patients with low-grade tumor (n ¼ 8), those in whom sublobar (n ¼ 5)
or incomplete (n ¼ 1) resection had been performed, and those with no
appropriate tissue sample from their tumors (n ¼ 12) were excluded. Two
patients who had died within the first 30 days postoperatively or in the hos-
pital were also excluded because the operative mortality is related to the sur-
gical procedure or functional limitations of the patients and was not relevant
to this study. In total, 141 patients with T1 (n¼ 26) or T2 (n¼ 115) and N0
M0 NSCLC were included in the study. Because this was a retrospectiveery c November 2010
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study committee of our hospital reviewed and approved the database.
The patients consisted of 15 (10.6%) women and 126 (89.4%) men at
a median age of 59 years (interquartile range [IQR], 54–64 years). Media-
stinoscopy was performed in 132 (93.6%) patients as part of routine
prethoracotomy mediastinal evaluation, and no mediastinal metastasis
was detected. In other patients computed tomographic analysis of the thorax
or positron emission tomographic analysis was used to eliminate the risk of
mediastinal lymphatic metastasis. Neoadjuvant chemotherapy and radio-
therapy were not provided. Systematic mediastinal lymphatic dissection
was performed during thoracotomy along with appropriate lung resection.
Lung resection consisted of lobectomy in 131 patients and pneumonectomy
in 10 (who have T2 tumors) patients (Table 1). No patient received adjuvant
therapy.
Resected specimens were sent to our pathology department for histo-
pathological and immunohistochemical examination. Specimens were fixed
in 10% formalin and embedded in paraffin. The longest diameter of each
tumor was measured, and one or two 4-mm-thick sequential sections were
obtained for each centimeter of the tumor from the areas that contained
the most dense viable tumor tissue. Several sections were subjected to rou-
tine hematoxylin and eosin staining, and others were kept for immunohisto-
chemical staining.
Tumors were staged after thoracotomy (pTNM) according to the 6th
International System for Staging Lung Cancer developed by the American
Joint Committee for Cancer in 1997.1 Histopathological tumor types were
determined according to the classification of the World Health Organiza-
tion.6 Histopathological tumor types and differentiations, T stages, and
tumor sizes are shown in Table 1.
VEGF expression level and microvessel density (MVD) based on
CD105 expression levels were determined by using immunohistochemical
staining by 2 pathologists who were blind to the survival results.
Immunohistochemical Staining
For each patient, one section that contained the most dense tumor tissue
was selected. Sections were taken onto adhesive (poly-L-lysine)–coated
slides, deparaffinized through a graduated xylene and alcohol series, and
then rehydrated in distilled water. Antigen retrieval was performed by add-
ing citrate buffer and heating in a microwave oven. Sections were incubated
in a 3% hydrogen peroxide solution to remove endogen peroxidase activity
and washed with a phosphate-buffered saline solution. The UV blocking
procedure was carried out to remove nonspecific immunoreactivity. Immu-
nohistochemical staining for VEGF to highlight VEGF expression and for
CD105 to highlight endothelial cells was performed by using a sensitive
streptavidin–biotinylated peroxidase complex system. All of the procedures
were performed in accordance with the antibody manufacturer’s protocols.
Sections were incubated with anti-VEGF mAb (Epitope Specific Rabbit An-
tibody, Vascular Endothelial Growth Factor, catalog no. RB-9031-R7) and
anti-CD105 mAb (Rabbit Polyclonal Antibody, CD105/Endoglin, TGF-b1/
3 Receptor, catalog no. RB-9291-R7) as primary antibodies (NeoMarkers;
Lab Vision Corp, Fremont, Calif). Then antigen–antibody complexes
were visualized with a biotin-labeled secondary antibody and streptavidin.
After this procedure, amino ethyl-carbazole chromogen (ScyTek Laborato-
ries, Inc, Logan, Utah) was applied to the sections. Then contrast staining
was performed with Mayer’s hematoxylin, and sections were covered
with a water-based mounting medium (Aqueous-Mount, ScyTec).The Journal of Thoracic and CaEvaluation of Tumor MVD
The 3 most vascular areas (hot spots) within a section were selected for
quantification of angiogenesis, and vessels labeled with the anti-CD105
mAb were counted under light microscopy at 4003 magnification. Each
single or connected endothelial cell stained red in these areas was counted
as a microvessel. The average counts were recorded as the CD105-MVD
for each case.
Evaluation of VEGF Expression Level
All tumor areas of the sections were examined, and the rate of tumor cells
stained with anti-VEGF was determined. Staining intensity was also deter-
mined as a rate. Tumors were graded according to the rate of stained cells as
follows: 0 for no stained cells, 1 for 1% to 25%, 2 for 26% to 50%, 3 for
51% to 75%, and 4 for greater than 75% of the tumor cells stained. Staining
intensity was also divided into 4 grades. Stained cells and staining intensity
grades were combined to form a total VEGF score.
Follow-up
Patients were followed up with regard to survival or recurrence at
6-month intervals routinely. Additionally, patients were called by telephone
to obtain further information during the preparation of this article. During
follow-up, tumor recurrence was discovered in 35 patients. For T1 stage dis-
ease, no local recurrence was seen, but distant metastases were observed in 4
patients. Local recurrence and distant metastases occurred in 8 and 23 pa-
tients with T2 stage disease, respectively. The survival period was calcu-
lated by using the day of hospital discharge as the first day and the day of
death or last contact as the final day. The median follow-up period was
47 months (IQR, 33–66 months). During the follow-up period, 44 patients
died (6 with T1 and 38 with T2 tumors). Causes of death were known in 31
(70.5%) patients; one of the patients with T1 disease had another primary
cancer (breast cancer) and died, another patients with T1 disease died
from distant metastasis, and 1 patient died from a cause unrelated to lung
cancer. However, the cause of death could not be established in the other
3 patients with T1 NSCLC. Three patients with T1 disease who had tumor
recurrences were still alive. Among 38 patients with T2 disease who died,
cause of death was tumor recurrence in 25. The cause of death was unrelated
to the tumor in 3 patients and was not known in the remaining 10 patients.
Six patients with T2 disease who had tumor recurrence were still alive.
Statistical Analysis
Cases were evaluated for demographic, surgical, and pathological
variables, and the distributions of these variables were compared by using
the c2 or Fisher’s exact tests. Correlations were determined by using the
Spearman rank correlation test. Patients’ survival was analyzed by using
the Kaplan–Meier method.
Differences in survival were determined by using the log-rank test on
univariate analysis, and prognostic factors with P values of less than .1
were included in a multivariate analysis by using the Cox proportional haz-
ards regression model.RESULTS
Adenocarcinoma histopathologic type was more common
(50%, n ¼ 13) in the T1 group compared with T2 group
(32%), and more T1 tumors (26%) were observed among
the patients with adenocarcinoma (vs 12% in the patients
with squamous cell cancer, P¼ .09). The overall 5-year sur-
vival of the patients was calculated as 68%. The effects of
histopathological type on survival were assessed, and the
5-year survival was found to be 75.1% for patients with
squamous cell carcinoma and 56.8% for patients withrdiovascular Surgery c Volume 140, Number 5 997
FIGURE 1. Survival curves of patients having non–small cell lung carci-
noma with high or low microvessel density (MVD).
TABLE 1. Prognostic factors revealed by means of univariate and
multivariate analyses in patients with completely resected T1 N0 M0
and T2 N0 M0 non–small cell carcinoma of the lung (n ¼ 141)
Univariate
P value
Multivariate
P value HR (95% CI)
Age .02 .003 1.06 (1.02–1.11)
Sex .21
Tumor size .09 .13
pT classification .4
Histology (squamous
vs adenocarcinoma)
.04 .22
Tumor differentiation .87
Surgical procedure .7
Perineural invasion .36
Lymphatic vessel invasion .42
Blood vessel invasion .006 .01 0.45 (0.24–0.84)
CD105 .02 .03 1.03 (1–1.06)
VEGF .91
HR, Hazard ratio; CI, confidence interval; VEGF, vascular endothelial growth factor.
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cally significant (P ¼ .04). The 5-year survival was 76.9%
for patients with stage T1 disease and 66.2% for those
with stage T2 disease. However, this difference was not sta-
tistically significant (P¼ .4). Sex, tumor differentiation, and
type of lung resection did not affect survival. In addition, no
significant differences were observed in the survivals of pa-
tients with and without lymph vessel or perineural invasion.
However, univariate analysis revealed that age, tumor size,
and invasion of the tumor to the tissue vasculature influ-
enced survival (Table 1).
No VEGF-positive cells were observed in 8 (5.7%) of the
141 tumors examined by using immunohistochemical stain-
ing. Thus the VEGF expression rate of stage I NSCLC was
94.3%. The median rate of cells that stained positively with
anti-VEGF antibody was 50% (IQR, 40%–70%). Anti-
VEGF–stained cell rate, VEGF staining intensity, and total
VEGF score did not influence survival at univariate analysis
(P ¼ .9, P ¼ .4, and P ¼ .9, respectively).
The mean MVD of the tumors determined by the level of
CD105 expression was 19.8  9.8, and survival was influ-
enced by MVD (P ¼ .02). The 5-year survivals of patients
with tumors having less than 20 microvessels or 20 or
more microvessels were 76.8% and 56.1%, respectively
(P ¼ .004, Figure 1). Tumor diameter did not influence sur-
vival in patients who had tumors with low vascularity (<20
microvessels, P ¼ .7).
A significant correlation was observed between the VEGF
expression level and the MVD of the tumors determined by
means of CD105 (P ¼ .0001); however, the correlation was
weak (R ¼ 0.4).
Factors that were found to affect survival on univariate
analysis (P<.1; ie, age, tumor size, histopathological tumor
type, vascular invasion of the tumor, and CD105-assessed
MVD) were used in a Cox regression analysis for multivar-998 The Journal of Thoracic and Cardiovascular Surgiate analysis of the factors that might have affected survival.
The analysis showed that MVD determined by the CD105
level was a factor that apparently and independently influ-
enced survival, along with age and blood vessel invasion
(Table 1).
Twenty-two (35.5%) of the 62 patients with high CD105-
assessed MVD and 13 (16.5%) of the 79 patients with low
MVD experienced recurrence or metastasis. This difference
in frequency was statistically significant (P ¼ .01).DISCUSSION
Many patients with NSCLC experience and die of relapse,
although surgical treatment is potentially curative.7 Staging
helps to predict the overall survival of a group of patients,
but predicting the prognosis of a specific patient with
NSCLC is not that reliable. Thus new prognostic factors
are required to determine the subgroup of patients in the
same stage who have relatively poor prognosis.
Inclusion of patients with all stages of cancer in a study
implemented to detect prognostic factors might impede the
discovery of effective factors. The effects of these new fac-
tors can remain relatively weak compared with T, N, and M
variables, which are known to strongly affect survival. We
included patients with early T-stage tumors without lymph
node or distant organ metastasis to minimize the effects of
these primary survival markers. This was expected to un-
cover the effects of other potentially useful factors, and there
is no any study specifically interested in the effect of angio-
genesis in this subgroup of patients.
The angiogenesis level of the tumor showed a prominent
effect on survival in some studies,3 and a high vascularity of
the tumor was shown to indicate the survival tendency of tu-
mor cells.8 Variables related to tumor angiogenesis have
been investigated in many other types of cancer and haveery c November 2010
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angiogenesis was recently demonstrated to have an effect
on the prognosis of patients with resected lung
cancer.8,11,12 One method of determining the angiogenesis
level of a tumor is to measure the microvessel density of
the tumor (ie, to directly determine the number of vessels
in the tumor); a greater number of microvessels signifies
strong angiogenesis.9,13 Tumor MVD, determined either
by panendothelial markers or CD105, has been shown to
be an indicator of poor survival in various types of
cancer4,11 and also a poor prognostic factor in lung
cancer.11 Koukourakis and colleagues13 concluded that tu-
mor MVD is a factor independently affecting the prognosis
of patients with lung cancer. CD105-assessed MVD, how-
ever, shows a significantly better correlation with survival
than other factors.14 In the present study CD105-assessed
MVD was also determined as a strong factor affecting the
survival of patients with stage I NSCLC. The multivariate
analysis also indicated that CD105-assessed MVD is an
independent factor affecting survival. In addition, a high
MVD was shown to be valuable for the detection of local re-
currence and distant metastasis.
Measurement of the proangiogenic factor levels in tumor
tissue or in the body fluids is a way to indirectly determine
the level of tumor angiogenesis. VEGF is the most potent
proangiogenic factor.5 Therefore the VEGF level in serum
or tumor tissue has been used to detect angiogenesis and
thus act as a prognostic indicator in patients with cancer.5
The VEGF level was determined based on the ratio of stained
cells in several studies, and staining intensity of the cells was
added as an additional factor in some other studies. Analysis is
rather subjective, and staining is highly influenced by labora-
tory conditions. In the present study we determined both the
ratio and the intensity; however, VEGF level did not influence
survival. Most previous studies reported that the VEGF level
is a poor prognostic factor of survival in patients with
cancer.12,14 Some of the studies that examined VEGF levels
in the tumorous masses of patients with NSCLC determined
the VEGF level to be an independent factor that influenced
patient survival.15,16 However, most studies indicated that
a high VEGF level was associated with a high MVD or
correlated with MVD.9,12,13,17 In this context VEGF is
believed to decrease survival by promoting angiogenesis. In
contrast, many studies failed to demonstrate an influence of
VEGF level on the survival of patients with lung cancer.18,19
These studies indicated that the VEGF level lacked
a reliable correlation with MVD. We determined a weak
correlation between VEGF level and MVD. Although
VEGF is the most important proangiogenic factor, it is only
one of the factors regulating angiogenesis. The angiogenesis
level of a tumor is under the control of various
proangiogenic and antiangiogenic factors; the net result for
angiogenesis is determined by the balance between these
factors and thus the formation of the angiogenic switch.The Journal of Thoracic and CaAn angiogenic switch will not form if strong
antiangiogenic factors exist in the environment, despite
increased expression of VEGF by the tumor.13 Thus high
levels of VEGF in a tumor might not always lead to increased
angiogenesis. These findings suggest that tumor MVD might
be superior to VEGF alone for predicting patient survival,
and the VEGF level might not be the most important factor
determining MVD.
The survival of a patient with NSCLC depends on numer-
ous factors, and accurately determining the prognosis of
a specific patient is not possible. However, the angiogenesis
level of the tumor is a useful factor that can be used in
predicting survival of patients with stage I NSCLC.
VEGF, a major factor that influences angiogenesis, is not
a reliable predictor of the survival of these patients or their
possibility of recurrence. However, CD105-assessed MVD
of tumors in stage I NSCLC is a reliable indicator of
a patient’s prognosis and the possibility of local or distant
recurrence of these tumors.
The present study also has some limitations. T stage was
not found to be a significant prognostic factor. Also, the
prognostic effect of the histopathological type disappeared
on multivariate analysis. These results could be related to
heterogeneous distribution. The rate of adenocarcinoma in
the T1 tumor group and the rate of T1 tumor in the adenocar-
cinoma group were relatively high. Therefore these effects
might have neutralized each other. Additionally, the effect
of T stage might not have been apparent because of small
sample size (only 26 patients with T1 disease). A second
limitation of the study is that we could not find the causes
of death in some cases.
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